Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Get Free Report) have received an average rating of "Hold" from the twelve ratings firms that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, seven have issued a hold rating and four have issued a buy rating on the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $6.64.
A number of analysts have weighed in on MRVI shares. Craig Hallum dropped their target price on shares of Maravai LifeSciences from $12.00 to $10.00 and set a "buy" rating on the stock in a report on Tuesday, May 13th. Robert W. Baird dropped their target price on shares of Maravai LifeSciences from $3.00 to $2.00 and set a "neutral" rating on the stock in a report on Tuesday, May 13th.
Read Our Latest Analysis on MRVI
Maravai LifeSciences Stock Performance
Shares of NASDAQ:MRVI traded down $0.12 on Wednesday, reaching $2.22. 1,184,537 shares of the company's stock were exchanged, compared to its average volume of 1,507,423. The firm has a market capitalization of $565.35 million, a price-to-earnings ratio of -1.95 and a beta of 0.28. Maravai LifeSciences has a fifty-two week low of $1.66 and a fifty-two week high of $9.95. The business's 50-day moving average is $2.40 and its two-hundred day moving average is $2.79. The company has a quick ratio of 5.17, a current ratio of 5.96 and a debt-to-equity ratio of 0.60.
Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) last issued its earnings results on Monday, May 12th. The company reported ($0.08) earnings per share for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.01). The business had revenue of $46.85 million for the quarter, compared to analyst estimates of $44.01 million. Maravai LifeSciences had a negative return on equity of 12.91% and a negative net margin of 67.14%. Maravai LifeSciences's revenue for the quarter was down 26.9% compared to the same quarter last year. As a group, equities research analysts forecast that Maravai LifeSciences will post -0.24 EPS for the current year.
Institutional Trading of Maravai LifeSciences
A number of large investors have recently modified their holdings of the company. Callan Family Office LLC bought a new position in Maravai LifeSciences in the 2nd quarter valued at about $25,000. Ethic Inc. bought a new position in Maravai LifeSciences in the 2nd quarter valued at about $26,000. McAdam LLC bought a new position in Maravai LifeSciences in the 1st quarter valued at about $31,000. Sherbrooke Park Advisers LLC bought a new position in Maravai LifeSciences in the 4th quarter valued at about $78,000. Finally, EntryPoint Capital LLC bought a new position in Maravai LifeSciences in the 1st quarter valued at about $32,000. Institutional investors and hedge funds own 50.25% of the company's stock.
Maravai LifeSciences Company Profile
(
Get Free ReportMaravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.
Featured Stories
Before you consider Maravai LifeSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maravai LifeSciences wasn't on the list.
While Maravai LifeSciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access